Target Audience
- Researchers, scientists, and professionals interested in understanding Arc Institute's origins, organizational structure, and current research activities.
- Scientists, engineers, and business development professionals following advances in AI-driven biology, genome editing, and drug discovery.
- Readers interested in alternative models of scientific research, long-term research funding, and the evolving relationship between universities, research institutes, and industry.
Executive Summary
- Arc Institute is an independent nonprofit biomedical research organization founded in Silicon Valley in 2021. It aims to overcome limitations of conventional scientific research systems by providing researchers with long-term, flexible funding.
- Through partnerships with Stanford University, UC Berkeley, and UCSF, Arc has developed a distinctive research model combining scientific independence with large-scale experimental and computational infrastructure.
- By 2025–2026, two major research priorities had emerged: the Virtual Cell Initiative, which uses AI to predict cellular behavior, and the Alzheimer's Disease Initiative, which seeks to understand disease mechanisms and develop new treatments.
- Arc has produced notable research outputs, including Evo 2, STATE, and the Virtual Cell Atlas. However, challenges remain in AI prediction accuracy, clinical translation, and the financial sustainability of a donation-dependent research model.
- Arc Institute's fundamental ambition extends beyond applying AI to biology. It seeks to reinvent the research organization itself by creating an environment where artificial intelligence and experimental biology can be integrated at scale.
1. What Is Arc Institute?
Arc Institute is an independent nonprofit biomedical research organization established in Silicon Valley in 2021 to develop a research model that differs from those of traditional universities and pharmaceutical companies.[1][2]
Its mission is to provide researchers with long-term, unrestricted research funding while combining the academic freedom associated with universities and the large-scale, coordinated research capabilities typically found in industry.
Initially, Arc envisioned supporting a broad range of fundamental research into complex diseases, including cancer, neurodegenerative disorders, and immune dysfunction.
As its technological infrastructure developed, two major institute-wide initiatives became increasingly prominent in 2025–2026: the development of AI models capable of predicting cellular behavior (Virtual Cell) and research into the mechanisms and treatment of Alzheimer's disease.[1][5][6]
Key Facts About Arc Institute
| Category | Details |
|---|---|
| Official name | Arc Institute |
| Founded | 2021 |
| Official launch date | December 15, 2021 |
| Location | Silicon Valley, California, United States |
| Organization type | Independent nonprofit biomedical research institute |
| Initial funding commitments | More than $650 million |
| Staff size reported on the official website | More than 400 people |
| Core Investigator appointment | Renewable eight-year term |
| Major university partners | Stanford University, University of California, Berkeley, and University of California, San Francisco (UCSF) |
| Major research initiatives | Virtual Cell Initiative and Alzheimer's Disease Initiative |
| Official website | https://arcinstitute.org/ |
Sources: Arc Institute's official website and UC Berkeley's announcement at the time of its establishment.[1][2][3]
The $650 million figure represents funding commitments announced in 2021. It should not be interpreted as Arc Institute's current asset balance.
Five Key Points for Understanding Arc Institute
First, Arc was created to address structural constraints in the scientific research environment, rather than simply to provide more funding.
Its institutional design seeks to reduce the pressure associated with continuously securing short-term grants and publishing research papers, allowing scientists to pursue ambitious projects over longer periods.
Second, Arc was founded by two life scientists and a technology entrepreneur.
The founders are Silvana Konermann of Stanford University, Patrick Hsu of UC Berkeley, and Patrick Collison, co-founder of Stripe.[1][2]
Third, Arc operates through a distinctive organizational model that sits between traditional academia and industry.
It directly employs researchers as an independent institute while maintaining close relationships with Stanford, UC Berkeley, and UCSF.
Fourth, Arc has evolved toward an integrated approach combining artificial intelligence and experimental biology.
One of its strengths is its ability to generate large volumes of biological data internally and use those data to develop and validate AI models.
Fifth, translating scientific discoveries into medical value remains an important challenge.
Although Arc has generated large datasets and promising fundamental research results, questions remain about whether these advances will lead to effective medicines and treatments, and whether its long-term funding and organizational model can remain sustainable.
2. The Origins and Evolution of Arc Institute
Understanding Arc Institute's founding requires looking beyond the goal of increasing research funding.
Its founders sought to address structural questions about how scientific research is conducted: what researchers can investigate, how much time they can devote to a problem, and how they can collaborate across disciplines.
2020: Collaboration Through Fast Grants
The three future co-founders collaborated through Fast Grants, a program designed to provide rapid funding for research related to COVID-19.
Their experience supporting urgent scientific projects helped shape the idea of creating a new kind of research institution.[2]
2021: The Official Establishment of Arc Institute
Arc Institute officially launched on December 15, 2021.
At its founding, the organization announced funding commitments exceeding $650 million.
Built upon partnerships with Stanford University, UC Berkeley, and UCSF, Arc was established as an independent research institute offering eight-year funding commitments and an environment designed to maximize scientific freedom.[2][3]
2022–2024: Building the Research Organization and Experimental Infrastructure
During this period, Arc expanded its research programs, including Core Investigators, Science Fellows, and Innovation Investigators.
It also developed five Technology Centers and strengthened cross-institutional collaborations involving its university partners.[1][4]
2025: Major Research Outputs in AI and Biology Begin to Emerge
In February 2025, Arc released the Virtual Cell Atlas, containing data from more than 300 million cells.
It also introduced biological AI models such as Evo 2 and STATE.
In June 2025, Arc launched its first Virtual Cell Challenge.[7][8][9]
This period can be understood as the beginning of a phase in which the institute's accumulated research infrastructure started producing large-scale scientific outputs.
2026: Advancing AI Models and Building an International Research Ecosystem
In March 2026, Evo 2 was published in Nature.
In August of the same year, Arc launched its second Virtual Cell Challenge, focusing on the ability of AI models to predict responses in previously unseen cellular environments.
In October, Arc also announced additional models and research results, including PIE and Bolero.[7][8][10]
Three Stages in Arc Institute's Development
Based on its publicly documented history, Arc Institute's development can be divided into three broad stages.
| Stage | Period | Main Characteristics |
|---|---|---|
| Stage 1 | 2021–2022 | Designing research funding systems and researcher support structures |
| Stage 2 | 2023–2024 | Recruiting scientific talent and building technological infrastructure |
| Stage 3 | 2025 onward | Generating large-scale AI and biological research outputs and expanding external engagement |
This is an analytical classification based on Arc Institute's published history, rather than an official framework used by the institute itself.
3. What Makes Arc Institute Different from Traditional Research Organizations?
3-1. Funding Researchers Rather Than Individual Research Projects
One of Arc Institute's most distinctive features is its renewable eight-year funding commitment for Core Investigators.[2][4]
In conventional competitive research funding systems, scientists typically submit detailed proposals, undergo periodic reviews, and report progress against predefined objectives.
At Arc Institute, researchers are selected based on their capabilities and potential, and they are given substantial freedom to pursue new directions, including changing their research topics.
A typical laboratory consists of approximately 8–18 people.
Arc also provides research infrastructure and administrative support, in addition to funding.
3-2. Comparing Universities, Biotechnology Companies, and Arc Institute
The following comparison highlights the characteristics of Arc Institute's research model.
| Dimension | Typical University Laboratory | Typical Biotechnology Company | Arc Institute |
|---|---|---|---|
| Primary funding sources | Competitive grants and university funding | Investment and business revenue | Donations and philanthropic funding |
| Research time horizon | Often several years, depending on grants | Determined by business plans | Eight-year commitments for Core Investigators |
| Research freedom | Generally high, but constrained by grants | Influenced by commercial objectives | High degree of scientific independence |
| Large-scale infrastructure | May depend on shared university facilities | Often developed internally | In-house Technology Centers |
| Research outputs | Publications, education, and training | Products, intellectual property, and commercial value | Fundamental research, technologies, and practical applications |
| Main constraints | Grant acquisition, teaching, and administration | Profitability and development timelines | Donation dependence and translation into practical outcomes |
The descriptions of universities and companies represent typical institutional models rather than universal characteristics. Information about Arc Institute is based on its official research model.[4]
Arc seeks to maintain the intellectual independence associated with university research while organizing specialized expertise and infrastructure on a scale more commonly seen in industry.
3-3. A Research Ecosystem Connected to Three Universities
Although Arc Institute is an independent organization, it collaborates closely with three universities.[1][3]
- Stanford University
- University of California, Berkeley
- University of California, San Francisco (UCSF)
Under this model, Arc researchers may hold faculty appointments at partner universities, while graduate students from those institutions may conduct doctoral research in Arc laboratories.
This arrangement allows Arc to leverage university research networks and educational systems while providing the funding and infrastructure of an independent research institute.
3-4. Distinct Roles for Researchers and Technical Specialists
Arc Institute organizes its scientific workforce into several categories.[1][4]
| Category | Role and Support |
|---|---|
| Core Investigators | Lead independent research laboratories primarily based at Arc, with guaranteed research funding through eight-year appointments. |
| Science Fellows | Early-career researchers, including recent PhD graduates, who receive support to establish small independent laboratories, including salaries and research funding. |
| Innovation Investigators | Researchers based at partner universities who receive five years of flexible research funding. |
| Technology Center Staff | Specialists in advanced experimental and computational technologies who support collaborative research and large-scale projects across laboratories. |
An important point is that Arc Institute does not simply recruit outstanding professors and principal investigators.
It also seeks to establish long-term professional roles for AI engineers, genomics specialists, experimental scientists, and other technical experts, allowing specialized research knowledge to accumulate within the organization.
3-5. Research Infrastructure Built Around Five Technology Centers
Arc Institute has established five Technology Centers that provide advanced research capabilities across multiple laboratories.[4]
| Technology Center | Main Technologies and Research Areas |
|---|---|
| Multiomics | Single-cell RNA analysis, spatial analysis, and proteomics |
| Genome Engineering | CRISPR, genome editing, and genetic perturbation |
| Cellular Models | Human cells, organoids, and tissue models |
| Mammalian Disease Models | Mammalian models and in vivo disease research |
| Computational | Machine learning, data infrastructure, and computational biology |
These centers are not merely shared facilities that perform experiments on request.
They also develop new research technologies and participate directly in designing scientific projects.
The Technology Centers support collaborations across different laboratories and large-scale initiatives such as the Virtual Cell Initiative and the Alzheimer's Disease Initiative.
This structure is particularly important when considering Arc Institute's competitive strengths.
4. Arc Institute's Current Research Priorities
At its founding, Arc Institute supported research across a broad range of areas, including cancer, neurodegeneration, and immune dysfunction.
Today, while individual scientists continue pursuing independent research, two major institute-wide initiatives have become prominent.[5][6]
- Virtual Cell Initiative
- Alzheimer's Disease Initiative
4-1. Virtual Cell Initiative: Predicting Cellular Responses with AI
The goal of the Virtual Cell Initiative is to use artificial intelligence to predict how cells respond to interventions such as drug treatments and genetic modifications.[5]
The Virtual Cell concept does not refer to recreating the visual appearance of cells using computer graphics.
Instead, it involves representing gene expression and functional cellular states mathematically, then using AI to predict how those states will change following interventions.
By combining large-scale experimental datasets with AI, Arc aims to develop systems capable of estimating biological responses even under conditions that have not been directly tested experimentally.
The research process can be organized into five stages.
Stage 1: Collect large-scale experimental data.
Researchers generate extensive biological datasets using technologies such as single-cell analysis, genetic perturbation, and drug treatment experiments.
Stage 2: Integrate datasets through the Virtual Cell Atlas.
Publicly available data and internally generated experimental data are standardized and organized for AI model training.
Stage 3: Train AI models.
Models such as STATE and PIE are trained to predict changes in cellular states.
Stage 4: Evaluate predictions under previously unseen conditions.
Benchmarks such as the Virtual Cell Challenge are used to assess model performance objectively.
Stage 5: Apply the models to drug target discovery and therapeutic candidate selection.
The long-term goal is to improve experimental efficiency and advance understanding of complex diseases.
However, this final stage represents a future research objective rather than an established clinical achievement.
Large-Scale Data Infrastructure as a Competitive Advantage
The Virtual Cell Atlas released in February 2025 contained data from more than 300 million cells.
By 2026, Arc reported that the Atlas contained more than 600 million cells' worth of observational and perturbation data.
Documentation for STATE also described training using observational data from 167 million cells and perturbation data from more than 100 million cells.[5][9]
What distinguishes this strategy is that Arc develops AI models while also generating and managing the large-scale experimental datasets required to train them.
Both model development and data production are integrated within the same organization.
4-2. Alzheimer's Disease Initiative: Understanding Disease Mechanisms and Developing Treatments
The Alzheimer's Disease Initiative seeks to understand how numerous genetic and environmental risk factors interact and to develop treatments that target the underlying mechanisms of the disease.[6]
Arc approaches Alzheimer's disease as a complex condition that cannot be adequately explained by a single gene or protein.
Its research therefore combines three-dimensional human brain tissue models, genetic perturbation, large-scale data analysis, and causal inference.
The main approaches are as follows.
Three-Dimensional Human Brain Models
Researchers use spheroids and organoids containing combinations of neurons, microglia, astrocytes, and other cell types.
Large-Scale Perturbation Experiments
Experiments modify genetic, immune, metabolic, and other conditions to observe responses associated with disease pathology.
Causal Inference
Researchers seek to identify biological pathways and targets through which different risk factors may exert shared effects.
Therapeutic Candidate Discovery
Identified targets are manipulated to determine whether disease-associated phenotypes can be improved.
Arc aims to extend these approaches beyond Alzheimer's disease by developing research methods that can also be applied to other complex diseases.
However, identifying promising therapeutic targets is not the same as developing treatments that are effective in patients.
Based on currently published information, it would be premature to conclude that the initiative has established clinically effective treatments.
5. Major Scientific Achievements
Arc Institute's achievements extend beyond disease-specific research to technologies that could significantly expand the methods available to biological scientists.
5-1. Evo 2: A Foundation Model for Biological Sequences
Evo 2 is an AI model trained on DNA sequences that can be used for tasks such as predicting the effects of mutations and designing new biological sequences.
It was developed through collaboration involving Arc Institute, NVIDIA, universities, and other research partners.
The model was released in 2025, and the research was published in Nature in March 2026.[10]
Evo 2 is notable for its potential as a general-purpose AI foundation for analyzing and designing large-scale biological sequences.
5-2. Bridge Recombinases: A New Genome Editing Technology
Bridge Recombinases are a technology that uses RNA to control DNA insertion, deletion, inversion, and other genetic rearrangements.
The technology was reported in Nature in 2024.
In 2025, research demonstrating its function in human cells was published in Science.
It has attracted attention as a potential new approach to genetic manipulation beyond CRISPR.[1]
5-3. STATE: An Early Virtual Cell Model
STATE is an AI model designed to predict how interventions involving genes or drugs affect cellular gene expression.
Its initial version was released in June 2025.[9]
It represents an important step toward implementing the Virtual Cell concept as a concrete predictive modeling problem.
5-4. Virtual Cell Challenge: Engaging the Global Research Community
The Virtual Cell Challenge is an international competition focused on predicting cellular responses using AI.
The first competition took place in 2025.
In 2026, the competition evolved to include zero-shot prediction tasks, requiring models to make predictions in previously unseen cellular environments.[7]
According to Arc Institute, more than 5,000 participants from 114 countries registered for the 2025 competition, and more than 1,200 teams submitted results.
The 2026 competition introduced more challenging prediction tasks involving six different cell lines.
This initiative is notable because it provides shared datasets and evaluation standards while encouraging participation from researchers outside Arc Institute.
It demonstrates Arc's ambition to do more than publish its own scientific results.
By openly distributing datasets, benchmarks, and AI models, Arc is seeking to establish a global research ecosystem in which scientists from many organizations can participate.
6. Challenges Facing Arc Institute
Arc Institute's distinctive research model also presents important challenges.
It is useful to distinguish between technical limitations explicitly acknowledged in its research publications and potential organizational or financial risks identified through analysis of its publicly available information.
6-1. Long-Term Financial Sustainability
Arc Institute relies on substantial philanthropic contributions.
Although it announced more than $650 million in funding commitments at its founding, expansion of its research activities also increases ongoing expenditure on personnel, experimental equipment, and computational resources.
Publicly available US nonprofit tax filings, known as Form 990, provide the following financial information.[11]
Revenue and Expenses Based on Public Tax Filings
Unit: USD millions
| Fiscal Year | Total Revenue | Total Expenses |
|---|---|---|
| 2021 | 15.4 | 6.5 |
| 2022 | 96.6 | 32.8 |
| 2023 | 53.6 | 64.2 |
| 2024 | 122.3 | 82.8 |
Source: ProPublica Nonprofit Explorer, based on IRS Form 990 filings.[11]
Key Financial Figures for Fiscal Year 2024
| Item | FY2024 |
|---|---|
| Total revenue | $122.28 million |
| Total expenses | $82.78 million |
| Contribution revenue | $120.45 million |
| Dependence on contributions | 98.5% |
| Year-end net assets | $100.72 million |
Revenue exceeded expenses in fiscal year 2024.
However, because contributions accounted for approximately 98.5% of revenue, maintaining donor support and fundraising capacity is likely to remain an important financial management challenge.
The $650 million announced at the time of establishment represents funding commitments made in 2021. It should not be confused with cash balances at the end of 2024 or unrestricted funds immediately available for research.
Furthermore, this analysis does not establish Arc Institute's complete financial position for 2025–2026.
Therefore, the available information does not justify concluding that Arc is currently experiencing a funding shortage or financial deterioration.
6-2. Predictive Accuracy and Generalization of Virtual Cell Models
AI-based cellular prediction is a highly promising research direction, but it is also technically challenging.
Arc Institute has acknowledged through its Virtual Cell Challenge activities that further improvements are needed in prediction accuracy, evaluation methods, and biological generalization.[7]
A particularly important question is whether a model trained on experiments involving one cell line can accurately predict responses in previously unseen cell lines or disease-related cells.
The focus on zero-shot prediction in the 2026 Virtual Cell Challenge reflects the importance of addressing this problem.
Even if an AI model can predict gene expression with high accuracy, that does not necessarily mean it can predict cellular functions, tissue-level disease processes, or patient responses to treatment.
6-3. Translating Fundamental Research into Medicines and Treatments
Since its establishment, Arc Institute has envisioned a Translation Program to help convert fundamental scientific discoveries into commercial and medical applications.[2][4]
This vision includes technology transfer to startups, intellectual property licensing, early-stage development funding, and networks of drug discovery experts.
However, substantial additional work is required to turn an understanding of disease mechanisms into effective treatments.
Important stages include:
- Confirming reproducibility in animal models and human-derived samples.
- Evaluating efficacy, safety, and methods of administration.
- Conducting clinical trials.
- Obtaining approval from regulatory authorities.
- Establishing manufacturing, distribution, and adoption in medical practice.
Currently available information primarily highlights fundamental research, model development, and therapeutic target discovery.
The extent to which treatments originating from Arc Institute advance into clinical development will be an important indicator to monitor.
6-4. Balancing Scientific Freedom with Large-Scale Organizational Research
A major strength of Arc Institute is its attempt to combine scientific independence with the ability to conduct large-scale collaborative research.
However, these objectives do not always align.
For example, an innovative research direction pursued by an individual Core Investigator may not directly correspond to the priorities of institute-wide projects such as Virtual Cell or Alzheimer's disease research.
The allocation of personnel, experimental facilities, and computational resources therefore raises important organizational questions.
Arc must balance the autonomy of individual scientists with the need to achieve results from coordinated research initiatives.
This is a potential challenge arising from the institution's design.
It does not imply that documented internal conflicts, misconduct, or organizational disputes have occurred.
6-5. Balancing Open Science and Intellectual Property
Arc Institute actively promotes the publication and distribution of research datasets, AI models, software, and benchmarks.[5][7]
At the same time, intellectual property protection and licensing arrangements become important when scientific discoveries are translated into commercially developed medicines or genome editing technologies.
The institute must therefore consider how to balance the scientific benefits of openness with the commercial incentives required for medical development.
This tension is likely to remain relevant as more of its research progresses toward practical applications.
7. How Should We Evaluate Arc Institute Today?
Based on its history and current activities, Arc Institute can be understood as more than a newly established biomedical research laboratory.
It represents an attempt to redesign research funding, talent organization, experimental infrastructure, AI development, and scientific dissemination as an integrated system.
7-1. Summary of Strengths and Challenges
| Evaluation Dimension | Current Assessment |
|---|---|
| Research funding flexibility | Distinctive eight-year funding commitments |
| Talent and organizational structure | Strong university partnerships and integration of technical specialists |
| Research infrastructure | Five Technology Centers and large-scale experimental capabilities |
| AI research | Published research outputs including Evo 2 and STATE |
| Open science | Development of shared datasets, AI models, and international benchmarking competitions |
| Medical translation | An important area requiring further validation |
| Financial sustainability | High dependence on philanthropic contributions represents a potential risk |
7-2. Key Indicators to Monitor Over the Next Three to Five Years
| Area | Key Questions |
|---|---|
| Virtual Cell | How much will predictive performance improve in previously unseen cellular and disease environments? |
| Alzheimer's Initiative | Will the research identify concrete therapeutic targets or preclinical candidates? |
| Scientific outputs | Will fundamental discoveries increasingly lead to clinical and industrial applications? |
| Financial sustainability | Will Arc maintain a stable donor base capable of supporting ongoing research expenditure? |
| Talent and organization | Can the institute sustain both scientific independence and large-scale collaboration? |
| External impact | To what extent will other organizations adopt and use Arc's publicly released datasets and models? |
8. Broader Implications: A New Model for Scientific Research
Three important developments emerge from Arc Institute's history and current research activities.
8-1. From a Research Funding Model to an Integrated Research Platform
At its founding, Arc Institute attracted particular attention for its commitment to long-term research funding.
Today, however, its activities encompass the organizational integration of advanced experimental facilities, specialized personnel, AI computing infrastructure, and large-scale biological datasets.
This evolution can be understood as a shift from simply providing resources to researchers toward providing an integrated environment in which scientific research can be conducted.
8-2. Combining Independent Research with Mission-Oriented Large-Scale Programs
Arc Institute respects the freedom of individual researchers while also pursuing major institute-wide scientific objectives.
It supports creative fundamental research while concentrating substantial resources on two large initiatives: Virtual Cell and Alzheimer's disease.
Balancing researchers' independence with large-scale coordinated research is both a distinctive institutional feature and an important long-term evaluation criterion.
8-3. Creating Data and Tools for the Broader Scientific Community
Arc Institute is investing not only in discoveries generated by its own researchers but also in datasets and tools that can be used by scientists elsewhere.
The Virtual Cell Atlas and Virtual Cell Challenge illustrate this approach.
Rather than keeping its scientific outputs within the organization, Arc aims to accelerate progress across the broader research community by providing access to data, models, and common evaluation standards.
8-4. Arc Institute's Research Model Still Requires Long-Term Validation
Arc Institute is a relatively young organization, having been established in 2021.
Its published fundamental research achievements are noteworthy, but more time will be required to determine whether its long-term funding model produces greater scientific and societal value than conventional research systems.
An especially important question is whether its distinctive organizational model can demonstrably accelerate scientific discovery, drug development, and medical translation.
9. Conclusion
Arc Institute is building a research environment that differs substantially from conventional academic and industrial models.
Its approach combines long-term funding commitments, university partnerships, the professional organization of technical specialists, and close integration between artificial intelligence and experimental biology.
Since its establishment in 2021, Arc has progressed from designing its institutional structure and research infrastructure to producing concrete scientific outputs such as Virtual Cell, Evo 2, and STATE in 2025–2026.
At the same time, important challenges remain.
These include the generalization capabilities of AI models in biology, the translation of discoveries into medicines and treatments, a financial structure dependent on philanthropic funding, and the organizational balance between independent research and major coordinated initiatives.
Arc Institute's fundamental ambition is not simply to apply artificial intelligence to life sciences. It is to create a new type of research organization designed specifically to enable the integration of AI and biology.
How effectively Arc translates this organizational model into scientific discoveries, medical applications, and industrial innovation will be an important development to watch in the future of biomedical research.
References
[1] Arc Institute, "About Arc Institute," Arc Institute. https://arcinstitute.org/about
[2] Arc Institute, "Introducing Arc Institute," Arc Institute, 2021. https://arcinstitute.org/news/introducing-arc-institute
[3] University of California, Berkeley, "UC Berkeley partners with new Arc Institute to tackle complex diseases," Berkeley News, 2021. https://news.berkeley.edu/2021/12/15/uc-berkeley-partners-with-new-arc-institute-to-tackle-complex-diseases/
[4] Arc Institute, "The Arc Model," Arc Institute. https://arcinstitute.org/model
[5] Arc Institute, "Virtual Cell Initiative," Arc Institute. https://arcinstitute.org/virtual-cell-initiative
[6] Arc Institute, "Alzheimer's Disease Initiative," Arc Institute. https://arcinstitute.org/alzheimers-disease-initiative
[7] Arc Institute, "2026 Virtual Cell Challenge," Arc Institute, 2026. https://arcinstitute.org/news/virtual-cell-challenge-2026
[8] Arc Institute, "News," Arc Institute. https://arcinstitute.org/
[9] Arc Institute, "Virtual Cell Initiative: Research and Models," Arc Institute. https://arcinstitute.org/virtual-cell-initiative
[10] Arc Institute, "Research and Publications," Arc Institute. https://arcinstitute.org/
[11] ProPublica, "Arc Research Institute — Nonprofit Explorer," ProPublica Nonprofit Explorer, IRS Form 990 filings, 2021–2024. https://projects.propublica.org/nonprofits/organizations/871920284
Editor's Note: This article is based on publicly available information as of November 4, 2026. Organizational size and research priorities are based on Arc Institute's official website. The primary financial filings reviewed extend through fiscal year 2024. Discussions of funding sustainability, organizational management, and intellectual property represent analysis of publicly available information and should not be interpreted as an acknowledgment by Arc Institute that these issues have become actual organizational problems.